Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06607939 · ClinicalTrials.gov registry record · Phase 1
ORB-021 In Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors Cancer, sponsored by Orionis Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT06607939 is a Phase 1 study of Advanced Solid Tumors Cancer that is actively recruiting participants, run by Orionis Biosciences. The registered enrollment target is 36 participants, below the 350-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06607939, a Phase 1 study of Advanced Solid Tumors Cancer, is actively recruiting participants, sponsored by Orionis Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical research study is to determine if an investigational new drug, named ORB-021, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by assessing the safety and potential activity in the treatment of solid tumors. There are three phases to this study: screening, treatment and end of treatment.
Conditions Studied
Interventions
- DRUG ORB-021
Study Locations (2)
Arizona
- Honor Health Clinical Research - Scottsdale
Texas
- MDAC - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06607939
The ClinicalTrials.gov registry entry for NCT06607939 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 350-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Orionis Biosciences, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors Cancer appearing as the primary indexed condition, and to 1 intervention - of which ORB-021 is the first listed.
NCT06607939 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Texas.
Frequently Asked Questions
What is clinical trial NCT06607939 about?
NCT06607939 is a clinical study titled "ORB-021 In Patients With Advanced Solid Tumors". The goal of this clinical research study is to determine if an investigational new drug, named ORB-021, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by ...
What is the current status of trial NCT06607939?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2024-11-21. Estimated completion is 2027-05.
What conditions does trial NCT06607939 study?
This clinical trial studies the following conditions: Advanced Solid Tumors Cancer.
What interventions are being tested in trial NCT06607939?
The interventions under investigation include: ORB-021 (DRUG).
Who is sponsoring clinical trial NCT06607939?
This trial is sponsored by Orionis Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06607939 being conducted?
This trial has 2 study locations across Arizona, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
RECRUITING · Phase 1
-
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.